Drug Profile
JNJ 54416076
Alternative Names: JNJ-54416076Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Janssen Research & Development
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Germany (PO, Suspension)
- 31 Oct 2016 Janssen Research & Development plans a phase I exploratory trial in Healthy volunteers in USA (PO, Tablet and Suspension) (NCT02951845)
- 01 Sep 2016 Janssen Research & Development completes a first-in-human phase I trial in Healthy volunteers in Germany (PO) (NCT02670395)